Premium
Prognostic significance of p16 in locally advanced squamous cell carcinoma of the head and neck treated with concurrent cisplatin and radiotherapy
Author(s) -
Lau Harold Y.,
Brar Sony,
Klimowicz Alexander C.,
Petrillo Stephanie K.,
Hao Desirée,
Brockton Nigel T.,
Kong Christina S.,
LeesMiller Susan P.,
Magliocco Anthony M.
Publication year - 2011
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.21439
Subject(s) - cish , medicine , immunohistochemistry , oncology , head and neck cancer , cisplatin , radiation therapy , head and neck squamous cell carcinoma , surrogate endpoint , human papillomavirus , regimen , cancer research , chemotherapy , in situ hybridization , messenger rna , biology , gene , biochemistry
Background Human papillomavirus (HPV)–related squamous cell cancer of the head and neck (SCCHN) has emerged as a distinct clinical entity. The expression of p16 protein can be used as a surrogate for HPV status. Methods p16 immunohistochemistry (IHC) was assessed in archival paraffin‐embedded material for 55 patients with locally advanced SCCHN treated with a uniform regimen of cisplatin and radiation. HPV status was assessed by colorimetric in situ hybridization (CISH) and polymerase chain reaction (PCR). Results Compared with p16‐ and HPV‐negative patients, the p16‐ and HPV‐positive patients had improved overall survival, disease‐free survival, and locoregional recurrence rates. Conclusions p16 IHC may serve as a useful surrogate and prognostic marker for patients with HPV‐related SCCHN treated with cisplatin and radiation. © 2010 Wiley Periodicals, Inc. Head Neck, 2011